CL2023000732A1 - Derivados de tetrahidroisoquinolina para el tratamiento de enfermedades de la sangre roja y enfermedades inflamatorias - Google Patents
Derivados de tetrahidroisoquinolina para el tratamiento de enfermedades de la sangre roja y enfermedades inflamatoriasInfo
- Publication number
- CL2023000732A1 CL2023000732A1 CL2023000732A CL2023000732A CL2023000732A1 CL 2023000732 A1 CL2023000732 A1 CL 2023000732A1 CL 2023000732 A CL2023000732 A CL 2023000732A CL 2023000732 A CL2023000732 A CL 2023000732A CL 2023000732 A1 CL2023000732 A1 CL 2023000732A1
- Authority
- CL
- Chile
- Prior art keywords
- inflammatory diseases
- treatment
- red blood
- blood disorders
- tetrahydroisoquinoline derivatives
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 208000019838 Blood disease Diseases 0.000 title 1
- 208000014951 hematologic disease Diseases 0.000 title 1
- 208000018706 hematopoietic system disease Diseases 0.000 title 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 1
- 101710114687 Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000019501 erythrocyte disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporcionan en la presente compuestos y composiciones de los mismos para activar el factor 2 relacionado con el factor 2 nuclear eritroide (Nrf2) para tratar las enfermedades de los eritrocitos y enfermedades inflamatorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078118P | 2020-09-14 | 2020-09-14 | |
| US202163229338P | 2021-08-04 | 2021-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000732A1 true CL2023000732A1 (es) | 2023-10-30 |
Family
ID=78080553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000732A CL2023000732A1 (es) | 2020-09-14 | 2023-03-14 | Derivados de tetrahidroisoquinolina para el tratamiento de enfermedades de la sangre roja y enfermedades inflamatorias |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230357270A1 (es) |
| EP (1) | EP4211134A1 (es) |
| JP (1) | JP2023544089A (es) |
| KR (1) | KR20230104126A (es) |
| CN (1) | CN116406364A (es) |
| AU (1) | AU2021340890A1 (es) |
| BR (1) | BR112023004567A2 (es) |
| CA (1) | CA3194774A1 (es) |
| CL (1) | CL2023000732A1 (es) |
| CO (1) | CO2023003083A2 (es) |
| CR (1) | CR20230158A (es) |
| DO (1) | DOP2023000050A (es) |
| EC (1) | ECSP23019518A (es) |
| IL (1) | IL301170A (es) |
| MX (1) | MX2023003036A (es) |
| PE (1) | PE20231363A1 (es) |
| WO (1) | WO2022056448A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018140876A1 (en) * | 2017-01-30 | 2018-08-02 | Biogen Ma Inc. | Nrf2 activator |
| WO2020116660A1 (en) * | 2018-12-05 | 2020-06-11 | Scohia Pharma, Inc. | Macrocyclic compound and use thereof |
-
2021
- 2021-09-14 WO PCT/US2021/050212 patent/WO2022056448A1/en active Application Filing
- 2021-09-14 CN CN202180076152.8A patent/CN116406364A/zh active Pending
- 2021-09-14 EP EP21787220.9A patent/EP4211134A1/en active Pending
- 2021-09-14 KR KR1020237012402A patent/KR20230104126A/ko unknown
- 2021-09-14 US US18/026,069 patent/US20230357270A1/en active Pending
- 2021-09-14 IL IL301170A patent/IL301170A/en unknown
- 2021-09-14 BR BR112023004567A patent/BR112023004567A2/pt unknown
- 2021-09-14 CR CR20230158A patent/CR20230158A/es unknown
- 2021-09-14 JP JP2023516063A patent/JP2023544089A/ja active Pending
- 2021-09-14 PE PE2023001157A patent/PE20231363A1/es unknown
- 2021-09-14 MX MX2023003036A patent/MX2023003036A/es unknown
- 2021-09-14 AU AU2021340890A patent/AU2021340890A1/en active Pending
- 2021-09-14 CA CA3194774A patent/CA3194774A1/en active Pending
-
2023
- 2023-03-13 DO DO2023000050A patent/DOP2023000050A/es unknown
- 2023-03-14 CL CL2023000732A patent/CL2023000732A1/es unknown
- 2023-03-14 CO CONC2023/0003083A patent/CO2023003083A2/es unknown
- 2023-03-16 EC ECSENADI202319518A patent/ECSP23019518A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023544089A (ja) | 2023-10-20 |
| MX2023003036A (es) | 2023-06-21 |
| AU2021340890A1 (en) | 2023-05-04 |
| IL301170A (en) | 2023-05-01 |
| CN116406364A (zh) | 2023-07-07 |
| BR112023004567A2 (pt) | 2023-04-04 |
| CA3194774A1 (en) | 2022-03-17 |
| US20230357270A1 (en) | 2023-11-09 |
| WO2022056448A1 (en) | 2022-03-17 |
| ECSP23019518A (es) | 2023-06-30 |
| EP4211134A1 (en) | 2023-07-19 |
| KR20230104126A (ko) | 2023-07-07 |
| CO2023003083A2 (es) | 2023-06-30 |
| CR20230158A (es) | 2023-07-13 |
| PE20231363A1 (es) | 2023-09-05 |
| DOP2023000050A (es) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000751A1 (es) | Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419) | |
| CL2021002995A1 (es) | (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| ECSP21027049A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| AR105808A1 (es) | Compuestos de amida para el tratamiento de trastornos médicos | |
| EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| UY28721A1 (es) | Derivados de sulfonamida para eltratamiento de enfermedades | |
| ECSP056164A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| UY28724A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| CL2021003098A1 (es) | Compuestos inmunomoduladores diméricos contra mecanismos basados en cereblon (divisional de la solicitud no. 202100061) | |
| PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
| AR090241A1 (es) | INHIBIDORES DE LA b-SECRETASA | |
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
| CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| CL2023000732A1 (es) | Derivados de tetrahidroisoquinolina para el tratamiento de enfermedades de la sangre roja y enfermedades inflamatorias | |
| CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
| ES2112832T3 (es) | Derivados carbamoilicos. | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| AR114282A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”) | |
| EA202092185A1 (ru) | Ингибиторы секреции белка на основе триазациклододекансульфонамида ("tcd") |